Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre — Funded Warrants
For best results when printing this announcement, please click on link below: Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to the development and commercialization of new medicines to improve